コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n elevated pulmonary vascular resistance and right heart failure.
2 d pulmonary vascular resistance and eventual right heart failure.
3 lar remodelling causing premature death from right heart failure.
4 No deaths were associated with right heart failure.
5 TV) is increasing and results in intractable right heart failure.
6 e progression of tricuspid regurgitation and right heart failure.
7 riuretic peptide levels, and the presence of right heart failure.
8 terized by pulmonary vascular remodeling and right heart failure.
9 ients with severe pulmonary hypertension and right heart failure.
10 te treatment strategies for PH and resultant right heart failure.
11 ere disorder of lung vasculature that causes right heart failure.
12 ypoxic pulmonary hypertension and ultimately right heart failure.
13 pulmonary arterial tree, eventually leads to right heart failure.
14 nt of pulmonary hypertension, and associated right heart failure.
15 n as a novel therapeutic strategy for PH and right heart failure.
16 in pulmonary vascular resistance leading to right heart failure.
17 -recognized but treatable etiology of severe right heart failure.
18 primary graft nonfunction or intraoperative right heart failure.
19 viduals present with dyspnoea or evidence of right heart failure.
20 years with death usually due to progressive right heart failure.
21 nsion with clear lungs, and disproportionate right heart failure.
23 st device implantation by moderate or severe right heart failure according to criteria from the Inter
24 the case of a young man who developed acute right heart failure after combined heart and kidney tran
26 ith change in HRQOL, baseline 3 months, were right heart failure and 3-month New York Heart Associati
27 r of systemic venous congestion, identifying right heart failure and adding incremental prognostic va
29 pulmonary hypertension is a risk factor for right heart failure and death after orthotopic heart tra
30 of the pulmonary vasculature that results in right heart failure and death, are usually assessed with
41 evealed a combination of left heart failure, right heart failure and moderate-to-severe tricuspid reg
42 c abnormalities that reflect the severity of right heart failure and predict adverse outcomes in pati
44 lier diagnosis and noninvasive monitoring of right heart failure and pulmonary hypertension that will
46 lung inflammation, vascular remodeling, and right heart failure and reverses hypoxic pulmonary hyper
47 ions primarily arrhythmias, thromboembolism, right heart failure and, in a subset of patients, pulmon
50 art tolerance, predict decompensation before right heart failure, and guide titration of device speed
51 th pulmonary hypertension, hypoxemia, and/or right heart failure, and may offer a new therapeutic app
53 nt with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic
54 or adverse events included bleeding, stroke, right heart failure, and percutaneous lead infection.
55 nts included postoperative bleeding, stroke, right heart failure, and percutaneous lead infection.
57 or outcomes, may mediate RV vulnerability to right heart failure, and represent promising candidates
58 ve clearer evidence now for predicting early right heart failure, and treating it in those patients w
59 antly left heart failure in combination with right heart failure, and tricuspid regurgitation; and (i
61 rized by heightened ventricular interaction, right heart failure, and worsening pulmonary vascular di
62 t estimates for bleeding, stroke, infection, right heart failure, arrhythmias, and rehospitalizations
63 ic iron levels, this model developed PAH and right heart failure as a consequence of intracellular ir
65 26 critically ill adult patients with acute right heart failure defined by echocardiographic criteri
66 e pulmonary hypertension precipitating acute right heart failure, despite administration of milrinone
68 OF REVIEW: To review recent publications on right heart failure developing early and late after impl
70 have provided good evidence about predicting right heart failure early after LVADs, though how to pre
73 n, retroperitoneal vascular constriction and right heart failure - has shown that serotonin and tachy
74 Patients with pulmonary hypertension and right heart failure have a high risk of clinical deterio
75 k of progressive tricuspid regurgitation and right heart failure in patients with moderate or lesser
79 ure early after LVADs, though how to predict right heart failure late after LVAD is still unclear as
81 cyclin can be life-saving when perioperative right heart failure occurs due to exacerbation of pulmon
82 determined to be the direct cause of death (right heart failure or sudden death) in 37 (44%) patient
83 d more severe disease as indicated by recent right heart failure (OR, 3.3 [95% CI, 2.8-3.9]) or respi
85 nt ischemic attack, LVAD thrombosis, or late right heart failure rates by 12 months on LVAD support.
86 ents with PAH and 75.7% of those who died of right heart failure received parenteral prostanoid thera
87 evices is associated with improved outcomes, right heart failure remains a considerable challenge.
89 ention that left heart failure has received, right heart failure remains understudied both at the pre
90 perience progressive symptoms of dyspnea and right heart failure resulting in significant morbidity a
94 amine reduces the incidence of postoperative right heart failure (RHF) in pediatric heart transplant
101 cured from explanted hearts of patients with right heart failure served as novel comparison samples.
102 d 1.10 (1.04-1.17), respectively, along with right heart failure symptoms of 2.03 (1.14-3.60), while
104 th respect to medical therapies for treating right heart failure, there is evidence for the use of bo
105 ar and biventricular assist devices, such as right heart failure, valvular regurgitation, cardiac arr
107 <0.001), and the incidences of pneumonia and right heart failure were lower than those in the CS grou
108 s with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery s
109 ped for treating patients with severe TR and right heart failure with prohibitive surgical risk.
110 animals after inducing an acute air embolism right heart failure, with all animals recovering stabili
111 ications (one constrictive pericarditis, two right heart failures without underlying infection, and o